网页
综合
更新时间 2025-05-30 00:00:00
Filoviruses
The filovirus family includes some of the world’s most deadly pathogens, including Zaire ebolavirus – commonly known as Ebola virus. CEPI’s filovirus investments focus on expanding access to licensed vaccines against Ebola virus, accelerating the development of Bundibugyo virus vaccines in response to the epidemic in Democratic Republic of the Congo, pioneering the development of broadly protective filovirus vaccines and a filovirus vaccine library, and supporting clinical trials of vaccine candidates for Marburg virus and Sudan ebolavirus during outbreaks.
CEPI has supported the generation of clinical trial data for both licensed vaccines for Zaire ebolavirus – commonly known as Ebola virus- including funding studies to help expand access for vulnerable populations including people living with HIV, pregnant women and infants. CEPI is now focused on helping to make Ebola vaccines sustainable for the future, which includes investment to update the manufacturing process of MSD’s vaccine to make it more accessible and affordable.
There are no licensed vaccines for Bundibugyo virus. In response to the 2026 epidemic, CEPI is urgently accelerating the development of a portfolio of Bundibugyo vaccine candidates.
CEPI is pioneering research into vaccines that could protect against multiple known filoviruses, with co-funding from the European Union’s Horizon Programme. The programme is making a vital contribution to the 100 Days Mission by generating important scientific knowledge for a ‘filovirus vaccine library’, intended to accelerate vaccine development against a future filovirus Disease X.
Currently no approved vaccines exist for Sudan ebolavirus or Marburg virus, both of which have caused multiple deadly disease outbreaks in Africa in recent years. CEPI has supported clinical trials of monovalent vaccine candidates against these filoviruses as part of country-led responses in Rwanda and Uganda. The organisation is funding the development of international antibody standards for Marburg virus – now established – and Sudan ebolavirus. These important scientific tools will help researchers to assess and compare the performance of experimental vaccines against the diseases.
CEPI’s outbreak response experts reflect on how Rwanda was able to implement an emergency trial of a Marburg vaccine just 10 days after the outbreak was declared.
©2026 CEPI. All rights reserved
CEPI has supported the generation of clinical trial data for both licensed vaccines for Zaire ebolavirus – commonly known as Ebola virus- including funding studies to help expand access for vulnerable populations including people living with HIV, pregnant women and infants. CEPI is now focused on helping to make Ebola vaccines sustainable for the future, which includes investment to update the manufacturing process of MSD’s vaccine to make it more accessible and affordable.
There are no licensed vaccines for Bundibugyo virus. In response to the 2026 epidemic, CEPI is urgently accelerating the development of a portfolio of Bundibugyo vaccine candidates.
CEPI is pioneering research into vaccines that could protect against multiple known filoviruses, with co-funding from the European Union’s Horizon Programme. The programme is making a vital contribution to the 100 Days Mission by generating important scientific knowledge for a ‘filovirus vaccine library’, intended to accelerate vaccine development against a future filovirus Disease X.
Currently no approved vaccines exist for Sudan ebolavirus or Marburg virus, both of which have caused multiple deadly disease outbreaks in Africa in recent years. CEPI has supported clinical trials of monovalent vaccine candidates against these filoviruses as part of country-led responses in Rwanda and Uganda. The organisation is funding the development of international antibody standards for Marburg virus – now established – and Sudan ebolavirus. These important scientific tools will help researchers to assess and compare the performance of experimental vaccines against the diseases.
CEPI’s outbreak response experts reflect on how Rwanda was able to implement an emergency trial of a Marburg vaccine just 10 days after the outbreak was declared.
©2026 CEPI. All rights reserved
本页为82搜索生成的网页快照，内容来自站内索引；演示数据的原文链接仅作示例。